Workflow
公司季度报告审议
icon
Search documents
宁波天益医疗器械股份有限公司第三届董事会第二十四次会议决议公告
Group 1 - The company held its 24th meeting of the third board of directors on April 25, 2025, with all 7 directors present, including one via telecommunication [2][4] - The board unanimously approved the proposal regarding the 2025 Q1 report, confirming that the report accurately reflects the company's operational status without any false records or significant omissions [3][5] - The proposal does not require submission to the shareholders' meeting for approval [6] Group 2 - The company also held its 20th meeting of the third supervisory board on April 25, 2025, with all 3 supervisors present [11][13] - The supervisory board unanimously approved the proposal regarding the 2025 Q1 report, affirming that the report is accurate and complies with legal requirements [11][12] - The decision of the supervisory board is legally valid as it met the quorum requirements [11][13]